COMMUNIQUÉS West-GlobeNewswire

NewGen Eliminates Convertible Note and Warrant Overhang with a Significant Investor, Enters Into Settlement Agreement Strengthening Capital Structure
16/06/2026
NewGen to repurchase all outstanding convertible notes and warrants previously held by a significant investor in move to strengthen its capital structure Settlement to eliminate potential dilution from convertible notes [...]
FibroBiologics Advances Patient Dosing for Phase 1/2 Clinical Trial of CYWC628 for the Treatment of Diabetic Foot Ulcers
16/06/2026
Company continues to advance CYWC628 manufacturing with second GMP drug product run released for shipment to Australia and a third run nearing completion HOUSTON, June 16, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. ( [...]
Quoin Pharmaceuticals Announces Positive Clinical Update from Ongoing Pediatric Netherton Syndrome Compassionate Use Program
16/06/2026
Four of Six Patients Participating in the Compassionate Use Program Were Classified as ‘Improved’ or ‘Significantly Improved’ from Baseline Assessment Across Key Clinical Endpoints All Six Patients Are Younger than 10 [...]
Calidi Biotherapeutics Receives Positive Pre-IND Feedback from US FDA for CLD-401 Indicating Agreement on its Current Development Strategy as it Advances Towards a First-in-Human Study
16/06/2026
IND enabling studies with CLD-401 to continue with IND submission targeted by end of 2026 as Calidi continues to explore regulatory filing for CLD-401 in Australia in parallel SAN DIEGO, June 16, 2026 (GLOBE NEWSWIRE [...]
Outlook Therapeutics Announces FDA Acceptance of Resubmitted Biologics License Application for ONS-5010/LYTENAVA™ (bevacizumab-vikg) as a Treatment for Wet AMD
16/06/2026
Prescription Drug User Fee Act (PDUFA) goal date of July 29, 2026 ISELIN, N.J., June 16, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard [...]
BioAge Labs Announces First Participant Dosed in QUELL-CV, a Phase 2 Proof-of-Concept Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Patients at Elevated Cardiovascular Risk
16/06/2026
Randomized, double-blind, placebo-controlled, dose-ranging trial evaluating three once-daily oral doses of BGE-102 in participants with elevated systemic inflammation and additional cardiovascular risk factors Primary [...]
Cingulate Issued First U.S. Patent for Lead ADHD Asset CTx-1301
16/06/2026
Exclusivity Extended into December 2042 KANSAS CITY, Kan., June 16, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug [...]
Sanuwave Health Updates Second Quarter 2026 Guidance
16/06/2026
Sanuwave updates guidance for Q2 2026 to $8.5 - $9.5 million Company on pace for record unit sales of applicators in Q2 Market disruption impacting Ultramist system sales EDEN PRAIRIE, Minn., June 16, 2026 (GLOBE [...]
CDT Equity Announces Debt Update and New Loan Facility
16/06/2026
NAPLES, Fla. and CAMBRIDGE, United Kingdom, June 16, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today announced that it has re-structured its debt, agreeing to pay off all [...]
Through the MUHC Foundation, one family helps fuel breakthrough in rare cancer research
16/06/2026
MONTREAL, June 16, 2026 (GLOBE NEWSWIRE) -- One family’s generosity is helping drive a major breakthrough in rare cancer research at the MUHC. Through the MUHC Foundation’s SDR Project, Jim Hindley, his granddaughter [...]
Optimi Health Launches Standardized Microdose Psilocybin Products for Clinical Research
16/06/2026
Two naturally derived finished drug products, at 1mg and 2mg, give research organizations the consistent, validated doses required for controlled studies New microdose formats extend Optimi's psilocybin range, which [...]
Wolverine Peptide Stack & Blend Introduced by Koi Peptides for Laboratory Research
16/06/2026
Sheridan, WY, June 16, 2026 (GLOBE NEWSWIRE) -- Koi Peptides (Koi Research Labs LLC) has introduced Wolverine Peptide Stack as a research-use-only peptide stack for laboratory research. The product combines BPC-157 and [...]
Le King Faisal Specialist Hospital présente la chirurgie robotique comme modèle de soins spécialisés axés sur l’innovation lors du congrès HLTH Europe 2026
16/06/2026
AMSTERDAM, 16 juin 2026 (GLOBE NEWSWIRE) -- Le King Faisal Specialist Hospital & Research Centre (KFSH) met en avant son leadership en chirurgie robotique à l’occasion de sa participation au congrès HLTH Europe 2026 [...]
Creative Medical Technology Holdings, Inc. Advances Project PHOENIX into Nationwide AI Driven Virtual Data Collection Phase for U.S. Veterans Exposed to Burn Pits and Toxic Hazards
16/06/2026
The regulatory approved CELZ-Biodefense platform is designed to scale to at least 1,000 veterans through AI-enabled mobile-app data collection and field-capable logistics Proprietary CELZ-Biodefense Toxic Exposure Atlas [...]
Une famille soutient la recherche sur les cancers rares par l’intermédiaire de la Fondation du CUSM
16/06/2026
MONTRÉAL, 16 juin 2026 (GLOBE NEWSWIRE) -- La générosité d’une famille permet de réaliser une percée majeure dans la recherche sur les cancers rares au CUSM. Dans le cadre du Projet SDR de la Fondation du CUSM, Jim [...]
Trinity Biotech Awarded Significant Orders for Over 2 Million TrinScreen HIV Tests And Reports Q1 2026 Financial Results
16/06/2026
– Orders reinforce strong demand outlook in global health markets and supports 2026 revenue and profitability targets – Company publishes Q1 2026 financial results with revenue in line with prior guidance & [...]
First Steps Developmental Services Expands School Partnership Program to Support Massachusetts Students and Educators
16/06/2026
Behavior Technician support, BCBA consultation, and school-based behavioral services help Massachusetts schools maintain continuity of support for students during staffing shortages, extended absences, and other [...]
Intelligent Bio Solutions Initiates Clinical Study Supporting FDA Clearance and Planned U.S. Market Entry
16/06/2026
Interference Study designed to validate system specificity in the presence of potentially interfering substances commonly encountered in real-world settings Company expects to complete the study by mid-July 2026, with [...]
MultiValent Biotherapies Launches with $27 Million Series A Financing to Advance Development of Targeted Prostate Cancer Drug Conjugate
16/06/2026
- First closing of $27 million Series A financing - - Funding will support Phase 1b/2a clinical trial of MVB-101, a prostate-specific membrane antigen x folate receptor alpha (PSMA x FRα) targeted drug conjugate - - [...]

Pages